Table 1.
| Children with TB | No TB Controls without tuberculosis |
||
|---|---|---|---|
| During TB treatment | After TB treatment | ||
| N | 40 | 32c | 41d |
| Age (years) | 7.5 (4.6–10.9) | 8.5 (5.0–11.3) | 8.1 (6.4–9.6) |
| Weight (kg) | 19.6 (15.1–25.4) | 23.4 (16.6–28.9) | 22.2 (17.6–26.8) |
| BMI (kg/m2) | 15.8 (15.1–17.1) | 16.1 (15.3–17.6) | 16.1 (15.3–16.8) |
| EFV dose in mg/kg of body weight | 13.9 (13.1–15.0) | 13.7 (12.42–15.14) | 13.4 (12.5–14.2) |
| Time on TB treatment (months) | 3.7 (2.1–5.8) | – | – |
| Time on ART (months) | 2.6 (1.6–4.6) | 7.2 (6.6–9.6) | 24.1 (9.1–49.3) |
| Sex, male/females (% males) | 17/23 (43%) | 12/20 (38%) | 23/18 (56%) |
| Genotyped (n) | 33 | 25 | 31 |
| Extensive metabolizere [n (%)] | 9 (27%) | 7 (28%) | 8 (26%) |
| Intermediate metabolizere [n (%)] | 15 (45%) | 13 (52%) | 21 (68%) |
| Slow metabolizere [n (%)] | 9 (27%) | 5 (20%) | 2 (6.5) |
ART, antiretroviral therapy; EFV, efavirenz; TB, tuberculosis.
a
Median (IQR) if not otherwise stated.
b
Characteristics reported are those for the first sampling occasion.
c
Eight children did not undergo repeated sampling after antituberculosis treatment: one died; ART regimen was changed in four; two were withdrawn for nonmedical reasons; one child was relocated out of the region.
d
Does not include one child with no detectable efavirenz concentrations, presumably due to poor adherence.
e
Composite CYP2B6 genotype based on 516G→T, 983T→C, and 15582C→T.